Posts tagged as:
Trends typically come and go, but it’s not necessarily true for the pharmaceutical sector. Things move at a slower pace due to setbacks and slow research. However, there are some changes coming in the next year, and here is what you need to look out for. [click to continue…]
{ 0 comments }
At the end of January, the FDA announced approval for Bexsero, a Novartis vaccine designed to protect against invasive meningococcal disease caused by the serogroup B bacteria, Neisseria meningitidis. [click to continue…]
{ 0 comments }
The combination therapy in a polypill approach for patients with cardiovascular disease received favor from various FDA officials and agency advisors. The polypill combination therapy concept has been around for a decade, but is not in use at this point. [click to continue…]
{ 0 comments }